• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRX alert in real time by email
    SC 13G/A 1 cormorant-imrx093024a4.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*



    Immuneering Corporation

    (Name of Issuer)

     

    Class A Common Stock

    (Title of Class of Securities)

     

    45254E107

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  45254E107
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Cormorant Asset Management, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     
     


     

    CUSIP No.  45254E107
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Bihua Chen
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IN
     
     


     

     

    CUSIP No. 45254E107
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Immuneering Corporation

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    245 Main St., Second Floor

    Cambridge, MA 02142

    Item 2.(a) Names of Person Filing:

    Cormorant Asset Management, LP

    Bihua Chen

    This statement is filed by (i) Cormorant Asset Management, LP ("Cormorant"), a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the Cormorant Funds and (ii) Bihua Chen ("Ms. Chen") with respect to the Shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 2.(b) Address of Principal Business Office:

    200 Clarendon Street, 52nd Floor

    Boston, MA 02116

     

    Item 2.(c) Citizenship:

    Cormorant Asset Management, LP - Delaware

    Bihua Chen - United States

     

    Item 2.(d) Title of Class of Securities

    Class A Common Stock (the "Shares")

     

    Item 2.(e) CUSIP No.:

    45254E107

     

    CUSIP No.  45254E107
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨

    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

          Not Applicable

     

    CUSIP No. 45254E107
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned

    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

    (b) Percent of class

    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    (ii) Shared power to vote or to direct the vote

    (iii) Sole power to dispose or to direct the disposition of

    (iv) Shared power to dispose or to direct the disposition of

    The information set forth in Rows 5 though 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a -11.

     

     
    CUSIP No. 45254E107
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           

     

     
    CUSIP No. 45254E107
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           
    Get the next $IMRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMRX

    DatePrice TargetRatingAnalyst
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    3/15/2024$20.00 → $15.00Buy
    Needham
    3/15/2024Outperform → Market Perform
    TD Cowen
    3/15/2024$16.00 → $3.00Buy → Hold
    Jefferies
    12/1/2023$20.00Buy
    Needham
    6/26/2023$25.00Outperform
    Oppenheimer
    4/19/2023$5.00 → $14.00Underweight → Equal-Weight
    Morgan Stanley
    4/19/2023$10.00 → $20.00Neutral → Buy
    Mizuho
    More analyst ratings

    $IMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hausman Diana bought $19,862 worth of shares (5,500 units at $3.61) (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      7/7/25 8:59:25 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF PEOPLE OFFICER Neufeld Leah R bought $2,499 worth of shares (700 units at $3.57), increasing direct ownership by 7% to 10,729 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      7/7/25 8:52:03 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Zeskind Benjamin J. bought $34,879 worth of shares (10,000 units at $3.49), increasing direct ownership by 0.43% to 2,312,852 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      7/3/25 9:12:08 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hausman Diana bought $19,862 worth of shares (5,500 units at $3.61) (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      7/7/25 8:59:25 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF PEOPLE OFFICER Neufeld Leah R bought $2,499 worth of shares (700 units at $3.57), increasing direct ownership by 7% to 10,729 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      7/7/25 8:52:03 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Zeskind Benjamin J. bought $34,879 worth of shares (10,000 units at $3.49), increasing direct ownership by 0.43% to 2,312,852 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      7/3/25 9:12:08 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Immuneering Corporation downgraded by Morgan Stanley

      Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight

      12/13/24 8:04:38 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Immuneering Corporation with a new price target

      Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      3/15/24 7:50:35 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Corporation downgraded by TD Cowen

      TD Cowen downgraded Immuneering Corporation from Outperform to Market Perform

      3/15/24 7:19:50 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are rising everywhere, but more dramatically in some places. According to a new analysis of CDC data, Maine currently has the highest rates among US states, while Utah has the lowest. However, another study found that survival rates for cancer patients on immunotherapy depend on their insurance coverage, whether it be through private, Medicaid, or those who are uninsured. With cases for several types of cancers, such as breast cancer, there is plenty of new tech innovation for diagnosis and treatments coming from the private sect

      7/10/25 9:20:00 AM ET
      $CLDI
      $IMRX
      $KZIA
      $NUVB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

      - Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill that aims to drive longer-lasting benefit by outpacing resistance mechanisms that cause cancer drugs to stop working - - Additional patent applications pending for atebimetinib directed to compounds, pharmaceutical compositions, and methods of use with expiration expected into 2044 - CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Immuneering (NASDAQ:IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announ

      7/9/25 8:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment.

      6/20/25 9:21:00 AM ET
      $GRAL
      $IMRX
      $INTS
      $ONCY
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $IMRX
    Financials

    Live finance-specific insights

    See more
    • Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

      - 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable - - Markedly favorable tolerability profile observed, demonstrating potential best-in-class profile - - Pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients planned for 2026 - - Company to host conference call at 8:00 a.m

      6/17/25 6:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

      CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a clinical-stage oncology company outpacing cancer to help pati

      6/16/25 8:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

      - Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial data for IMM-1-104 monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled acros

      1/7/25 7:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    SEC Filings

    See more
    • SEC Form 424B5 filed by Immuneering Corporation

      424B5 - Immuneering Corp (0001790340) (Filer)

      6/23/25 6:30:48 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Corporation filed SEC Form 8-K: Other Events

      8-K - Immuneering Corp (0001790340) (Filer)

      6/17/25 6:09:26 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Immuneering Corp (0001790340) (Filer)

      6/16/25 8:44:04 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      11/14/24 4:15:35 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      11/14/24 3:03:47 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      4/15/24 6:10:57 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

      - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE

      5/7/24 4:05:00 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

      CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization

      3/12/24 8:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

      - Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predicted - - Study timeline for IMM-1-104 accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024- - Pharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected - - Completed $30 million underwritten offering; Projected cash runway extended into 2025 - CAMBRIDGE, Mass., May

      5/4/23 4:05:00 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care